Migraine is among the most disabling neurological conditions in the world, and the World Health Organization ranks it as a leading cause of years lived with disability in adults under 50. The pain itself is only part of the burden. Nausea, light and sound sensitivity, cognitive slowing, and post-attack exhaustion often matter more than head pain. For a subset of people, attacks are frequent and hard to treat, and the condition becomes a chronic illness rather than an occasional headache.
The trigeminovascular mechanism
A migraine is not simply dilated blood vessels, an idea that dominated for decades and is now considered incomplete. The current model centers on activation of the trigeminal nerve and the release of calcitonin gene-related peptide, or CGRP, from nerve endings around cranial blood vessels. CGRP dilates vessels and promotes neurogenic inflammation, and it sensitizes the nerve fibers that carry pain signals. This is why drugs that block CGRP or its receptor work in many patients.
The aura that precedes some attacks has a separate mechanism called cortical spreading depression. A wave of neuronal depolarization moves slowly across the cortex at roughly 2 to 3 millimeters per minute, followed by suppression of activity. As it travels, it produces the expanding visual or sensory disturbance many people recognize. Brain imaging shows this wave is real and measurable, not a subjective report.
Why does the brain become hypersensitive between attacks? Repeated activation lowers the threshold for future attacks, a process called central sensitization. The trigeminal nucleus and higher pain pathways become more responsive, so ordinary stimuli such as light, sound, or neck movement begin to trigger pain. This explains why frequent attacks can make the nervous system progressively more reactive.
Quantified burden
Global estimates put migraine prevalence at roughly 14 to 15 percent of adults, with a three-to-one female predominance after puberty. Peak prevalence falls in the 30s and 40s, the decades when work and caregiving demands are highest. The Global Burden of Disease studies rank migraine second among all causes of disability worldwide when measured in years lived with disability.
Attack frequency varies widely. Episodic migraine is defined as fewer than 15 headache days per month; chronic migraine is 15 or more, with at least eight qualifying as migraine. Roughly 2 to 3 percent of people with episodic migraine transition to chronic each year. The duration of an untreated attack typically runs 4 to 72 hours, though post-attack symptoms can linger a day or more.
Disability is not proportional to pain intensity alone. In a large international survey, about half of respondents reported severe impairment or needing bed rest during attacks. Many reported reduced productivity at work, and a substantial minority missed work entirely. The economic burden includes direct care, lost wages, and reduced output, and it falls disproportionately on working-age women.
The attack timeline
| Phase | Typical timing | What happens |
|---|---|---|
| Prodrome | Hours to 2 days before | Fatigue, mood change, food craving, neck stiffness |
| Aura | 20 to 60 minutes | Visual, sensory, or language disturbance; not everyone has one |
| Headache | 4 to 72 hours untreated | Throbbing pain, nausea, light and sound sensitivity |
| Resolution | Hours | Sleep or vomiting may relieve symptoms |
| Postdrome | Up to 1 day | Exhaustion, cognitive fog, lingering sensitivity |
The prodrome is underrecognized and often mistaken for stress or poor sleep. Recognizing it matters because treatment started early in an attack works better than treatment started after pain peaks.
Edge cases and red flags
Most headaches are not dangerous, but some presentations require urgent evaluation. Consider these warning signs:
A sudden, severe headache that peaks within seconds to a minute, sometimes called a thunderclap headache. Headache with fever, stiff neck, confusion, or a new neurological deficit. New headache after age 50, or a marked change in an established pattern. Headache that begins after head injury, or that worsens with coughing or posture change. New or escalating headache during pregnancy or the postpartum period.
Children and older adults often present atypically. Children may have shorter attacks, prominent abdominal symptoms, and less clearly lateralized pain. Older adults may develop new migraine-like headaches, but new onset late in life warrants evaluation for secondary causes. Menstrual-related migraine clusters around the drop in estrogen before menses and often responds less well to acute treatment.
Misconceptions worth correcting
A common belief is that migraine is just a bad headache. Brain imaging and clinical criteria show otherwise; it is a neurological disorder with sensory, autonomic, and cognitive components. Another misconception is that all migraines have aura. In fact, most attacks occur without aura, and the presence or absence of aura describes the attack, not the severity.
People often assume medication is harmless if used occasionally. Overuse of acute pain relievers can cause medication-overuse headache, a paradoxical worsening driven by frequent use of analgesics, triptans, or combination products. The exact threshold varies by drug, and the pattern of escalating use is the signal to discuss with a clinician.
A counterintuitive point for professionals: pain intensity and disability correlate weakly. A moderate attack with severe nausea and cognitive fog can disable more than a severe attack that responds quickly to treatment. This is why trials increasingly measure function and quality of life, not just pain scores.
Comparing acute and preventive options
| Approach | Purpose | Typical use window | Key limitation |
|---|---|---|---|
| NSAIDs | Acute relief | Early in attack | GI and kidney risk with frequent use |
| Triptans | Acute relief | Early in attack | Not for people with certain cardiovascular conditions |
| Antiemetics | Symptom control | Any stage | Treats nausea, not the attack |
| CGRP monoclonal antibodies | Prevention | Scheduled monthly or quarterly | Cost and access; not universal response |
| Beta-blockers | Prevention | Daily | Fatigue, exercise intolerance |
| Topiramate | Prevention | Daily | Cognitive side effects |
Treatment selection depends on attack frequency, disability, comorbidities, and patient preference. No single option works for everyone, and response rates vary. Combining acute and preventive strategies is common in moderate to severe disease.
Practical actions and thresholds
Track attacks for at least four to eight weeks before changing strategy, recording date, duration, severity, triggers, and treatment response. Bring this record to a clinician; it supports diagnosis and reveals patterns that memory misses.
Consider preventive treatment when attacks are frequent enough to disrupt work or life, generally several per month, or when acute treatment is poorly tolerated or overused. Do not delay acute treatment once an attack is clearly developing; earlier treatment is more effective. Treat nausea early, and use a dark, quiet space if light and sound worsen symptoms.
Maintain regular sleep, meals, and hydration, and limit alcohol if it reliably triggers attacks. Caffeine can help acutely but can also worsen rebound patterns if used heavily. Ask about pregnancy safety before starting any treatment, because several standard options require alternatives.
Limits of what we know
The mechanisms above are well supported, but individual triggers and treatment responses are not reliably predictable. Genetic studies show migraine is polygenic, with many small contributions rather than one cause. Diet and lifestyle changes help some patients and do little for others, and evidence for many popular triggers is based on patient reports rather than controlled trials.
Costs and access to newer CGRP-targeted drugs vary by insurance and country, so local advice matters more than general rules. Clinician guidance on acute drug selection and dosing should come from a treating professional, because individual cardiovascular and gastrointestinal risk changes the calculus. What the science establishes is the reality and severity of the disease; what it cannot do is prescribe a single path for every person.